Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDMDNYSE:INFUNASDAQ:LUCDNASDAQ:LUNG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDMDBaird Medical Investment$4.90-1.6%$5.49$1.05▼$12.50$32.26M-0.74396,990 shs3,370 shsINFUInfuSystem$5.41-6.7%$5.30$4.61▼$9.97$113.70M1.7393,988 shs175,434 shsLUCDLucid Diagnostics$1.59+19.5%$1.35$0.68▼$1.80$172.02M1.28525,101 shs3.04 million shsLUNGPulmonx$3.11-0.3%$5.07$2.97▼$9.37$125.20M0.65314,882 shs228,443 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDMDBaird Medical Investment-1.61%-3.73%-26.20%-7.55%+489,999,900.00%INFUInfuSystem-6.72%-12.03%+8.20%-29.28%-27.96%LUCDLucid Diagnostics+19.55%+26.19%+23.26%+8.90%+73.77%LUNGPulmonx-0.32%-9.33%-37.68%-65.29%-65.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AN/AN/AINFUInfuSystem2.454 of 5 stars2.00.00.00.03.04.21.9LUCDLucid Diagnostics3.1966 of 5 stars3.65.00.00.02.91.70.6LUNGPulmonx3.2109 of 5 stars4.33.00.00.01.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDMDBaird Medical Investment 0.00N/AN/AN/AINFUInfuSystem 4.00Strong Buy$13.00140.30% UpsideLUCDLucid Diagnostics 3.20Buy$3.50120.13% UpsideLUNGPulmonx 2.67Moderate Buy$11.59272.76% UpsideCurrent Analyst Ratings BreakdownLatest BDMD, LUNG, LUCD, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/26/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.003/25/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDMDBaird Medical Investment$37.04M0.87N/AN/AN/A∞INFUInfuSystem$137.58M0.83$0.42 per share12.79$2.47 per share2.19LUCDLucid Diagnostics$4.17M41.22N/AN/A($0.47) per share-3.38LUNGPulmonx$87.47M1.43N/AN/A$3.09 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDMDBaird Medical InvestmentN/AN/A0.00∞N/AN/AN/AN/AN/AINFUInfuSystem$870K$0.1490.1817.45N/A1.12%2.78%1.41%N/ALUCDLucid Diagnostics-$52.67M-$1.34N/AN/AN/A-1,069.87%N/A-123.54%8/11/2025 (Estimated)LUNGPulmonx-$60.84M-$1.44N/AN/AN/A-67.31%-55.36%-33.53%7/30/2025 (Estimated)Latest BDMD, LUNG, LUCD, and INFU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDMDBaird Medical InvestmentN/AN/AN/AINFUInfuSystem0.501.981.59LUCDLucid DiagnosticsN/A1.181.14LUNGPulmonx0.407.706.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDMDBaird Medical Investment19.78%INFUInfuSystem71.13%LUCDLucid Diagnostics74.01%LUNGPulmonx91.04%Insider OwnershipCompanyInsider OwnershipBDMDBaird Medical Investment78.90%INFUInfuSystem11.40%LUCDLucid Diagnostics6.80%LUNGPulmonx6.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDMDBaird Medical InvestmentN/A6.58 million1.39 millionN/AINFUInfuSystem41021.02 million19.10 millionOptionableLUCDLucid Diagnostics70108.19 million54.12 millionNo DataLUNGPulmonx25040.26 million37.24 millionOptionableBDMD, LUNG, LUCD, and INFU HeadlinesRecent News About These CompaniesPulmonx Co. (NASDAQ:LUNG) Shares Sold by Jacobs Levy Equity Management Inc.May 20, 2025 | marketbeat.comPulmonx Co. (NASDAQ:LUNG) Receives $12.07 Consensus Price Target from AnalystsMay 20, 2025 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 19, 2025 | marketbeat.com82,070 Shares in Pulmonx Co. (NASDAQ:LUNG) Purchased by Mercer Global Advisors Inc. ADVMay 15, 2025 | marketbeat.comWhy Pulmonx Corporation’s (LUNG) Stock Is Down 5.82%May 10, 2025 | aaii.comDeerfield Management Company L.P. Series C Purchases New Position in Pulmonx Co. (NASDAQ:LUNG)May 10, 2025 | marketbeat.comIt’s Time to Recognize COPD as a Women’s Health IssueMay 8, 2025 | medscape.comPulmonx Corporation (NASDAQ:LUNG) Q1 2025 Earnings Call TranscriptMay 6, 2025 | msn.comD. Boral Capital Reaffirms Buy Rating for Pulmonx (NASDAQ:LUNG)May 3, 2025 | marketbeat.comPulmonx (LUNG) Expected to Announce Quarterly Earnings on WednesdayMay 2, 2025 | marketbeat.comPulmonx to Present at the Bank of America Securities 2025 Health Care ConferenceMay 1, 2025 | globenewswire.comQ1 2025 Pulmonx Corp Earnings CallMay 1, 2025 | finance.yahoo.comBoothbay Fund Management LLC Sells 63,206 Shares of Pulmonx Co. (NASDAQ:LUNG)May 1, 2025 | marketbeat.comPulmonx Corp (LUNG) Q1 2025 Earnings Call Highlights: Strong International Growth Amid Domestic ...May 1, 2025 | uk.finance.yahoo.comPulmonx projects 20% long-term growth amid expanded initiatives and $12B market opportunityMay 1, 2025 | msn.comPulmonx Corporation (LUNG) Q1 2025 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comPulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue EstimatesApril 30, 2025 | zacks.comPulmonx Reports First Quarter 2025 Financial ResultsApril 30, 2025 | globenewswire.comPulmonx Co. (NASDAQ:LUNG) Shares Purchased by Renaissance Technologies LLCApril 30, 2025 | marketbeat.comPulmonx's Earnings OutlookApril 29, 2025 | benzinga.comBirchview Capital LP Purchases Shares of 51,000 Pulmonx Co. (NASDAQ:LUNG)April 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?PepsiCo’s Stock Price Is Disconnected From Reality: Time to BuyBy Thomas Hughes | April 28, 2025View PepsiCo’s Stock Price Is Disconnected From Reality: Time to BuyBDMD, LUNG, LUCD, and INFU Company DescriptionsBaird Medical Investment NASDAQ:BDMD$4.90 -0.08 (-1.61%) As of 05/23/2025 03:04 PM EasternBaird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.InfuSystem NYSE:INFU$5.41 -0.39 (-6.72%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.44 +0.03 (+0.55%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Lucid Diagnostics NASDAQ:LUCD$1.59 +0.26 (+19.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.64 +0.04 (+2.83%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Pulmonx NASDAQ:LUNG$3.11 -0.01 (-0.32%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.11 0.00 (0.00%) As of 05/23/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
